Open AccessPB2105: REAL WORLD EXPERIENCE WITH POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR R/R DLBCL IN 3 ACADEMIC CENTERS IN MADRID, SPAIN.
Author(s) -
Corrochano M.,
Nistal S.,
Pradillo V.,
Alonso A.,
Alaez C.,
TerceroMora M.,
Delgado I.,
Sanchez J. M.,
Marti E.,
Segado A.,
Benzo G.,
Escudero A.,
FernándezRañada J. M.,
Martinez Chamorro C.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000851252.20807.1c
Subject(s) - medicine , rituximab , bendamustine , discontinuation , adverse effect , refractory (planetary science) , regimen , gastroenterology , tolerability , salvage therapy , neutropenia , surgery , lymphoma , chemotherapy , physics , astrobiology